Shunho Shares Report Strong Growth in 2024 Half-Year Results

Business by 2FIRSTS.ai
Aug.19.2024
Shunho Shares Report Strong Growth in 2024 Half-Year Results
Shanghai Shunho released its 2024 semi-annual report, with a 29.98% revenue increase, focusing on e-cigarette and industrial hemp projects.

On August 17th, Shanghai Shunho New Material Technology Co., Ltd. (Stock abbreviation: Shunho shares, stock code: 002565) released its semi-annual report for the year 2024.

Shunho Shares Report Strong Growth in 2024 Half-Year Results


A report shows that the company achieved operating revenue of approximately 706 million yuan during the reporting period, an increase of 29.98% year-on-year. However, the company's business in the field of new tobacco products has decreased, with operating revenue of 2,700,885.54 yuan, accounting for 0.38% of the total operating revenue of the company, a decrease of 30.65% from the same period last year. This may be due to factors such as changes in market environment, policy adjustments, or company strategic realignments. The operating revenue from e-cigarette projects was 4.66 million yuan, while the industrial hemp project had operating revenue of 83,500 yuan.

Shunho Shares Report Strong Growth in 2024 Half-Year Results


According to reports, Shunho's subsidiary Greencore has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette processing companies in the new tobacco field. Its invested company, Meizhonglian, has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette product manufacturing companies. Meanwhile, Shunho's subsidiary Yilong has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette brand holding companies for domestic sales.


The company stated that its subsidiary Shunho Yilong's "Yilong" brand e-cigarette has been launched in some retail stores in Beijing, Shenzhen, and Shanghai areas, and will continue to promote the listing of "Yilong" products in multiple locations in the future.


In addition, the company's wholly-owned subsidiary Yunnan Lvxin has obtained the "Yunnan Province Industrial Hemp Processing License," which means the company is qualified to process industrial hemp in Qujing City, Yunnan Province. To seize the rapidly growing opportunities in the overseas industrial hemp market, Shunho Corporation has established a subsidiary, Kinneloa Holdings Inc., in the United States. With legal qualifications to carry out industrial hemp processing and manufacturing related business in the US, as well as sales in other legal countries and regions worldwide. Kinneloa Holdings Inc.'s wholly-owned subsidiary, E1011 Labs, has launched ELON second-generation HNB devices and Stelo heating rod products.


Another wholly-owned subsidiary of the company, Vitaldiol Pharmaceutical, has launched the Vitaldiol – R Series (Recover, Relief, Rest) products and Essential elixirs for the US market. These products contain ingredients such as CBD, NMN (Nicotinamide Mononucleotide), turmeric, melatonin, and others, emphasizing a "minimalist ingredients" and "natural health" concept.


The report mentioned that the global e-cigarette market is expected to continue growing, and the company stated that they will increase research and development investment to further expand the new tobacco industry both domestically and overseas.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Pakistan Plans to Implement Mandatory Standards for Nicotine Pouches; Industry Calls for Protection of Local Manufacturers
Pakistan Plans to Implement Mandatory Standards for Nicotine Pouches; Industry Calls for Protection of Local Manufacturers
Senior officials of the Pakistani government have instructed the Ministry of Science and Technology and the Standards and Quality Control Authority to accelerate actions to include tobacco-free nicotine oral products in the list of mandatory standards. The standards for nicotine pouches were initially drafted during the COVID-19 pandemic, specifying ingredient disclosure, upper limits on nicotine content per pouch, labeling, and child safety warnings. However, the process was stalled due to bure
Aug.26
InterTabac 2025 Insights|Altria Brings Two Nicotine Pouch Brands—On! and FUMi to InterTabac
InterTabac 2025 Insights|Altria Brings Two Nicotine Pouch Brands—On! and FUMi to InterTabac
2Firsts’ on-site reporting at InterTabac 2025 in Dortmund, Germany, found that Altria exhibited two nicotine pouch brands: On! and FUMi.
Sep.19 by 2FIRSTS.ai
Tamarind Intelligence: Regulation Will Determine Whether New Nicotine Products Achieve Their Potential
Tamarind Intelligence: Regulation Will Determine Whether New Nicotine Products Achieve Their Potential
At InterTabac 2025, Pablo Cano Trilla of Tamarind Intelligence highlighted the $80 billion global nicotine market, with e-cigarettes leading in North America and heated tobacco in EMEA. He stressed that regulations, bans, and stricter enforcement will shape the industry's growth and improve its image.
Sep.19
Spanish Anti-Tobacco Group Urges 10-Year “Cooling-Off” Ban on Ex-Officials Working for Tobacco Industry
Spanish Anti-Tobacco Group Urges 10-Year “Cooling-Off” Ban on Ex-Officials Working for Tobacco Industry
Spanish advocacy group Nofumadores.org has called for urgent reforms to Spain’s conflict-of-interest rules to bar politicians and senior civil servants from taking jobs in the tobacco industry for 10 years after leaving office. The appeal follows a series of hires by Philip Morris, Japan Tobacco International (JTI) and distributor Logista that the group says risk undermining ongoing anti-tobacco legislation. The Health Ministry, led by Mónica García, aims to expand smoke-free spaces, raise tobac
Sep.08
Guernsey Island proposes £2 tax on every 10ml of e-liquid in upcoming 2026 budget, sparking concerns among retailers and consumers
Guernsey Island proposes £2 tax on every 10ml of e-liquid in upcoming 2026 budget, sparking concerns among retailers and consumers
Guernsey Island plans to levy £2 tax (about $2.60) on every 10ml e-liquid, sparking concerns among retailers.
Aug.20 by 2FIRSTS.ai
2Firsts Exclusive: Dr. Zdinak Analyzes FDA’s Rejection of blu, Citing Lack of Behavioral Evidence
2Firsts Exclusive: Dr. Zdinak Analyzes FDA’s Rejection of blu, Citing Lack of Behavioral Evidence
In a 2Firsts exclusive, ARAC’s Dr. Zdinak explains FDA’s blu rejection stems from weak behavioral science data and urges companies to strengthen Module 6 studies immediately.
Aug.20